SCHEMBL6668459

SCHEMBL6668459

O=C(NCCc1ccc(Cl)cc1)c1cnc2cc(F)ccc2c1O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.49
CNR1 P21554 1/20 0.48
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
MAPT P10636 5/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.45
GAA P10253 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
GFER P55789 1/20 0.45
TP53 P04637 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6671834 0.91 ALDH1A1 (0.51) EGLN1CNR1RAB9ANPC1MAPT
SCHEMBL6199161 0.89 EGLN1 (0.47) EGLN1RAB9ALMNACYP1A2CYP2D6
SCHEMBL6667789 0.84 MAPT (0.56) EGLN1RAB9ANPC1MAPTLMNA
SCHEMBL6200449 0.80 PTGER4 (0.48) EGLN1LMNAALDH1A1CYP1A2GAA
SCHEMBL6199742 0.79 EGLN1 (0.51) EGLN1RAB9ANPC1LMNASMN1; SMN2
SCHEMBL6199469 0.76 EGLN1 (0.48) EGLN1RAB9ANPC1LMNASMN1; SMN2
SCHEMBL6199118 0.76 EGLN1 (0.47) EGLN1RAB9ANPC1MAPTLMNA
SCHEMBL6196111 0.76 EGLN1 (0.47) EGLN1RAB9ANPC1LMNASMN1; SMN2
SCHEMBL6198892 0.76 NR3C1 (0.48) EGLN1RAB9ANPC1MAPTLMNA
SCHEMBL6199043 0.75 EGLN1 (0.45) EGLN1LMNAALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004019932-A1 METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS PHARMACIA & UPJOHN COMPANY (US) 2004-03-11 WO disclosed